US Edition
Celltrion's Uplyma Records 24% Market Share in Europe.
Summary by businesskorea.co.kr
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Celltrion's autoimmune disease treatment, Uplyma (ingredient: adalimumab), is experiencing unprecedented growth across Europe. According to pharmaceutical market research firm IQVIA, Uplyma achieved a 24% market share in Europe in the first quarter of this year, a 3 percentage point increase in prescription sales compared to the previous quarter. This represents a mere 1 percentage point difference from the leading product. The driving force be…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium